Protective effects of trimetazidine on ischaemic myocardial dysfunction

S. L. Chierchia, G. Fragasso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Experimental and clinical studies have shown that trimetazidine has a number of potentially useful cytoprotective features. The drug has been reported to limit intracellular acidosis, sodium and calcium accumulation, to preserve contractile function and to limit cytolysis and membrane damage caused by oxygen free radicals. All these effects contribute towards reducing the deleterious effects of ischaemic insult. Improved cellular function during ischaemia could explain the beneficial effects of trimetazidine on resting and dobutamine-induced myocardial ischaemic dysfunction. Preserving mitochondrial function and energy metabolism from chronic oxygen deprivation may reduce ischaemic left ventricular dysfunction. Experimental studies also suggest that trimetazidine acts by affecting myocardial substrate utilization because the drug inhibits oxidative phosphorylation and utilization of fatty acid substrates and shifts metabolism from fatty acid to glucose oxidation. As these effects occur in the absence of detectable changes in systemic and coronary haemodynamics, the in vivo effects of trimetazidine on ischaemic myocardium are likely to depend on direct cytoprotection.

Original languageEnglish
JournalEuropean Heart Journal, Supplement
Volume1
Issue numberO
Publication statusPublished - 1999

Fingerprint

Trimetazidine
Fatty Acids
Drug Utilization
Dobutamine
Cytoprotection
Oxidative Phosphorylation
Left Ventricular Dysfunction
Acidosis
Energy Metabolism
Free Radicals
Reactive Oxygen Species
Myocardium
Ischemia
Hemodynamics
Sodium
Oxygen
Calcium
Glucose
Membranes
Pharmaceutical Preparations

Keywords

  • Coronary disease
  • Left ventricular function
  • Myocardial ischaemia
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Protective effects of trimetazidine on ischaemic myocardial dysfunction. / Chierchia, S. L.; Fragasso, G.

In: European Heart Journal, Supplement, Vol. 1, No. O, 1999.

Research output: Contribution to journalArticle

@article{eaadc9b88f784aaa8b41e2c1b2917529,
title = "Protective effects of trimetazidine on ischaemic myocardial dysfunction",
abstract = "Experimental and clinical studies have shown that trimetazidine has a number of potentially useful cytoprotective features. The drug has been reported to limit intracellular acidosis, sodium and calcium accumulation, to preserve contractile function and to limit cytolysis and membrane damage caused by oxygen free radicals. All these effects contribute towards reducing the deleterious effects of ischaemic insult. Improved cellular function during ischaemia could explain the beneficial effects of trimetazidine on resting and dobutamine-induced myocardial ischaemic dysfunction. Preserving mitochondrial function and energy metabolism from chronic oxygen deprivation may reduce ischaemic left ventricular dysfunction. Experimental studies also suggest that trimetazidine acts by affecting myocardial substrate utilization because the drug inhibits oxidative phosphorylation and utilization of fatty acid substrates and shifts metabolism from fatty acid to glucose oxidation. As these effects occur in the absence of detectable changes in systemic and coronary haemodynamics, the in vivo effects of trimetazidine on ischaemic myocardium are likely to depend on direct cytoprotection.",
keywords = "Coronary disease, Left ventricular function, Myocardial ischaemia, Trimetazidine",
author = "Chierchia, {S. L.} and G. Fragasso",
year = "1999",
language = "English",
volume = "1",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "O",

}

TY - JOUR

T1 - Protective effects of trimetazidine on ischaemic myocardial dysfunction

AU - Chierchia, S. L.

AU - Fragasso, G.

PY - 1999

Y1 - 1999

N2 - Experimental and clinical studies have shown that trimetazidine has a number of potentially useful cytoprotective features. The drug has been reported to limit intracellular acidosis, sodium and calcium accumulation, to preserve contractile function and to limit cytolysis and membrane damage caused by oxygen free radicals. All these effects contribute towards reducing the deleterious effects of ischaemic insult. Improved cellular function during ischaemia could explain the beneficial effects of trimetazidine on resting and dobutamine-induced myocardial ischaemic dysfunction. Preserving mitochondrial function and energy metabolism from chronic oxygen deprivation may reduce ischaemic left ventricular dysfunction. Experimental studies also suggest that trimetazidine acts by affecting myocardial substrate utilization because the drug inhibits oxidative phosphorylation and utilization of fatty acid substrates and shifts metabolism from fatty acid to glucose oxidation. As these effects occur in the absence of detectable changes in systemic and coronary haemodynamics, the in vivo effects of trimetazidine on ischaemic myocardium are likely to depend on direct cytoprotection.

AB - Experimental and clinical studies have shown that trimetazidine has a number of potentially useful cytoprotective features. The drug has been reported to limit intracellular acidosis, sodium and calcium accumulation, to preserve contractile function and to limit cytolysis and membrane damage caused by oxygen free radicals. All these effects contribute towards reducing the deleterious effects of ischaemic insult. Improved cellular function during ischaemia could explain the beneficial effects of trimetazidine on resting and dobutamine-induced myocardial ischaemic dysfunction. Preserving mitochondrial function and energy metabolism from chronic oxygen deprivation may reduce ischaemic left ventricular dysfunction. Experimental studies also suggest that trimetazidine acts by affecting myocardial substrate utilization because the drug inhibits oxidative phosphorylation and utilization of fatty acid substrates and shifts metabolism from fatty acid to glucose oxidation. As these effects occur in the absence of detectable changes in systemic and coronary haemodynamics, the in vivo effects of trimetazidine on ischaemic myocardium are likely to depend on direct cytoprotection.

KW - Coronary disease

KW - Left ventricular function

KW - Myocardial ischaemia

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=0032807951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032807951&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032807951

VL - 1

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - O

ER -